Genetix Biotherapeutics
A Senior Manager, QA Computer System Validation (CSV) at Genetix Biotherapeutics oversees the validation and compliance of GxP-regulated computerized systems, ensuring they meet global regulatory requirements and internal procedures. The role involves QA oversight for system implementations, upgrades, and decommissioning, as well as managing data integrity programs and supporting audits.
Headquarters
Somerville, Massachusetts, United States
Company Size
1-10 employees
Founded
1993
Genetix Biotherapeutics, formerly bluebird bio, is a biotechnology company focused on developing and commercializing transformative one-time genetic therapies for patients with rare diseases, including sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. The company markets three FDA-approved therapies—LYFGENIA, ZYNTEGLO, and SKYSONA—which are designed to treat the underlying genetic cause of disease using the patient's own blood stem cells. As a privately held company, Genetix Biotherapeutics is focused on commercial execution, scaling patient access, and improving the treatment experience for patients and providers.
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO
4 days ago
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots
Sep 18, 2025
After buyout, bluebird bio hatches familiar new branding as Genetix Biotherapeutics
Sep 18, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Genetix Biotherapeutics.
32% above the average for this role
Genetix Announces 2025 Commercial Performance Results and Outlines 2026 Strategic Priorities
1 week ago